A Study of Evacetrapib and Rifampin in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected.

For each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

NCT01695954

Hyperlipidemia HIV

COMPLETED PHASE1

A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men

NCT02138799

Drug-Drug Interaction (DDI) Healthy Subjects Pharmacokinetics of Enzalutamide

COMPLETED PHASE1

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

NCT04459598

Healthy Subjects Drug-drug Interaction Pharmacokinetics +1 more

COMPLETED PHASE1

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

NCT06698016

Healthy

COMPLETED PHASE1

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

NCT01585038

Cardiovascular Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Evacetrapib

Period 1:

130 milligram (mg) evacetrapib administered orally, once on Day 1

Group Type EXPERIMENTAL

Evacetrapib

Intervention Type DRUG

Administered orally

Evacetrapib + Rifampin

Period 2:

Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)

Evacetrapib: 130 mg administered orally once on Day 16

Group Type EXPERIMENTAL

Evacetrapib

Intervention Type DRUG

Administered orally

Rifampin

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evacetrapib

Administered orally

Intervention Type DRUG

Rifampin

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY2484595

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly healthy males and females (of non child-bearing potential)
* Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2), inclusive, at screening

Exclusion Criteria

* Have known allergies to evacetrapib, rifampin, related compounds or any components of either formulation, or history of significant allergic disease as determined by the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes